VBI Vaccines (NASDAQ:VBIV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIVFree Report) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Down 2.5 %

VBIV opened at $0.65 on Tuesday. The stock’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.80. VBI Vaccines has a one year low of $0.45 and a one year high of $19.65.

VBI Vaccines (NASDAQ:VBIVGet Free Report) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.24). The business had revenue of $6.62 million for the quarter, compared to the consensus estimate of $13.25 million. VBI Vaccines had a negative net margin of 1,403.15% and a negative return on equity of 199.61%. Equities analysts forecast that VBI Vaccines will post -2.16 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Engineers Gate Manager LP purchased a new position in VBI Vaccines during the 1st quarter worth $26,000. Point72 Hong Kong Ltd purchased a new position in VBI Vaccines during the 2nd quarter worth $29,000. Y Intercept Hong Kong Ltd purchased a new position in VBI Vaccines during the 2nd quarter worth $131,000. BNP Paribas Arbitrage SA increased its holdings in VBI Vaccines by 208.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 47,668 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 32,227 shares during the period. Finally, Centiva Capital LP purchased a new position in VBI Vaccines during the 2nd quarter worth $45,000. 19.08% of the stock is currently owned by hedge funds and other institutional investors.

VBI Vaccines Company Profile

(Get Free Report)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

See Also

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.